Dr. Su Wins Postdoctoral Recognition Award from the Society for Biomaterials
Dr. Su has been honored with the Postdoctoral Recognition Award from the Society for Biomaterials as part of the society’s 2025 award recipients, celebrating achievement in the biomaterials field.
The Postdoctoral Recognition Award highlights Dr. Su’s contributions to biomaterials science, particularly in areas that intersect with immune modulation and translational therapeutics. The Society for Biomaterials annually acknowledges individuals whose work advances materials research that enhances human health and quality of life—a mission directly aligned with Dr. Su’s commitment to cutting-edge science.
Dr. Su has built a reputation for translational research at the intersection of biomaterials and immunotherapy, developing novel biomaterial platforms that can effectively modulate the immune system for therapeutic benefit.
Being selected for the Postdoctoral Recognition Award not only acknowledges Dr. Su’s scientific achievement but also elevates her profile within the biomaterials and immunotherapy research communities. This award provides a platform to share Dr. Su’s work with peers, industry partners, and potential collaborators at the 2025 Society for Biomaterials Annual Meeting, expanding the impact of her research. As she continues her work on biomaterial-based immunotherapies, this recognition reinforces her goal in driving innovation that bridges fundamental research and clinical application.
About the Su Lab
The Su Lab at UCLA is advancing the frontiers of cell engineering to develop transformative immunotherapies for cancer, autoimmune diseases, and beyond. We bring together biomolecular engineering, nanotechnology, immunology, and cell engineering to build platform technologies that reshape how immune therapies work. By focusing on antigen specificity, precision immune modulation, and disease-tailored cellular responses, we aim to overcome the major barriers that limit current treatments—such as non-specific immune activation, severe side effects, and poor outcomes against solid tumors.